{"id":72029,"date":"2026-08-01T01:25:53","date_gmt":"2026-07-31T23:25:53","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2026\/08\/01\/il-22-synergizes-with-il-17-to-promote-mucosal-inflammation-and-bone-loss\/"},"modified":"2026-08-01T01:25:53","modified_gmt":"2026-07-31T23:25:53","slug":"il-22-synergizes-with-il-17-to-promote-mucosal-inflammation-and-bone-loss","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2026\/08\/01\/il-22-synergizes-with-il-17-to-promote-mucosal-inflammation-and-bone-loss\/","title":{"rendered":"IL-22 synergizes with IL-17 to promote mucosal inflammation and bone loss"},"content":{"rendered":"<div>\n<p><b>J Immunol<\/b>. 2026 Jul 10;215(7):vkag186. doi: 10.1093\/jimmun\/vkag186.<\/p>\n<p><b>ABSTRACT<\/b><\/p>\n<p>Interleukin (IL)-22 mediates immune cell communication with nonhematopoietic cells and was shown to exert protective or destructive effects in different disease contexts. In the oral mucosal disease periodontitis, IL-22 has been associated with increased tissue destruction, although cause-and-effect evidence and the underlying mechanisms are lacking. Here, we showed that endogenous IL-22 was required for experimental periodontitis in mice, whereas local administration of exogenous IL-22 exacerbated periodontal inflammation and bone loss. Importantly, the ability of IL-22 to induce expression of inflammatory cytokines and tissue-degrading metalloproteinases as well as cause bone loss required intact IL-17 function, suggesting a potential cooperation between the two cytokines. As human fibroblasts prominently coexpress IL-22 and IL-17 receptors in the periodontal tissue and play a role in the pathogenesis of periodontitis, we examined them in vitro as potential targets of a destructive IL-22-IL-17 interplay. IL-22 synergized with IL-17 for enhanced nuclear factor \u03baB-mediated inflammatory responses (IL-6, matrix metalloproteinase-1) in a STAT3-dependent manner. Analysis of cytosolic and nuclear extracts revealed that IL-22 enhanced nuclear factor \u03baB p65 phosphorylation and translocation to the nucleus of IL-17-stimulated fibroblasts. In conclusion, our study provides causal evidence for IL-22 involvement in periodontitis and describes a hitherto unknown IL-22-IL-17 synergy in inflammatory bone loss.<\/p>\n<p>PMID:<a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/42536770\/?utm_source=SimplePie&amp;utm_medium=rss&amp;utm_content=2985117R&amp;ff=20260731192552&amp;v=2.20.0.post5+40e1b98\">42536770<\/a> | DOI:<a href=\"https:\/\/doi.org\/10.1093\/jimmun\/vkag186\">10.1093\/jimmun\/vkag186<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>J Immunol. 2026 Jul 10;215(7):vkag186. doi: 10.1093\/jimmun\/vkag186. ABSTRACT Interleukin (IL)-22 mediates immune cell communication with nonhematopoietic cells and was shown to exert protective or destructive effects in different disease contexts. In the oral mucosal disease periodontitis, IL-22 has been associated with increased tissue destruction, although cause-and-effect evidence and the underlying mechanisms are lacking. Here, we &#8230; <a title=\"IL-22 synergizes with IL-17 to promote mucosal inflammation and bone loss\" class=\"read-more\" href=\"https:\/\/inmuno.es\/index.php\/2026\/08\/01\/il-22-synergizes-with-il-17-to-promote-mucosal-inflammation-and-bone-loss\/\" aria-label=\"Read more about IL-22 synergizes with IL-17 to promote mucosal inflammation and bone loss\">Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[42,71],"tags":[],"class_list":["post-72029","post","type-post","status-publish","format-standard","hentry","category-publicaciones","category-the-journal-of-immunology"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/72029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=72029"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/72029\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=72029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=72029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=72029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}